Immuno-oncology is a challenging field, with changes to the standard-of-care occurring rapidly across many different solid and hematologic malignancies. Fast-moving updates in IO occur for agents such as PD-(L)1 inhibitors, CTLA-4 inhibitors, novel checkpoint inhibitors, immune agonists, tumor microenvironment targeting agents, and CAR-T therapies. Our IO and tumor-area experts continuously collaborate to assess these changes and updates for emerging products that could challenge treatment algorithms in the near-future.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Late Stage Immuno-Oncology to help guide strategic and tactical commercial development decisions for market participants.